Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 9/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.43 |
| ▸ | NPY4R | P50391 | 6/20 | 0.42 |
| ▸ | NPY1R | P25929 | 4/20 | 0.42 |
| ▸ | NPY2R | P49146 | 2/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.42 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 2/20 | 0.42 |
| ▸ | REN | P00797 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11644393 | 1.00 | OPRK1 (0.43) | OPRK1OPRM1NPY4RNPY1RNPY2R | |
| SCHEMBL9616907 | 1.00 | OPRK1 (0.43) | OPRK1OPRM1NPY4RNPY1RNPY2R | |
| SCHEMBL31481586 | 0.97 | OPRK1 (0.47) | OPRK1OPRM1NPY4RNPY1RNPY2R | |
| SCHEMBL30118984 | 0.96 | OPRK1 (0.47) | OPRK1OPRM1CXCR4 | |
| SCHEMBL31467772 | 0.95 | EPHA2 (0.41) | OPRK1OPRM1NPY4RNPY1RNPY2R | |
| SCHEMBL30909420 | 0.91 | OPRK1 (0.53) | OPRK1OPRM1CXCR4 | |
| SCHEMBL30909432 | 0.91 | OPRK1 (0.53) | OPRK1OPRM1CXCR4 | |
| SCHEMBL30909422 | 0.91 | OPRK1 (0.53) | OPRK1OPRM1CXCR4 | |
| SCHEMBL30909428 | 0.91 | OPRK1 (0.53) | OPRK1OPRM1CXCR4 | |
| SCHEMBL30909423 | 0.91 | OPRK1 (0.53) | OPRK1OPRM1CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119874810-A | Tetrapeptide with blood sugar reducing effect and preparation and application thereof | 杭州康源食品科技有限公司 | 2025-04-25 | — | — | CN | claimed |
| CN-116675741-B | Application of intermediate in preparation of goserelin | 杭州湃肽生化科技有限公司 | 2023-10-31 | — | — | CN | claimed |
| CN-116675741-A | Application of intermediate in preparation of goserelin | 杭州湃肽生化科技有限公司 | 2023-09-01 | — | — | CN | claimed |
| US-H1056-H | Luteinizing hormone-releasing hormone | RHONE-POULENC CHIMIE, SERVICE BREVETS CHIMIE (FR) | 1992-05-05 | — | — | US | claimed |
| JP-3005499-A | — | — | None | — | — | JP | disclosed |
| US-20260053885-A1 | PHARMACEUTICAL COMPOSITIONS | RHYTHM PHARMACEUTICALS INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-12285460-B2 | Pharmaceutical compositions | RHYTHM PHARMACEUTICALS, INC. (US) | 2025-04-29 | — | — | US | disclosed |
| US-12064422-B2 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-08-20 | — | — | US | disclosed |
| WO-2024108009-A1 | DYRK/CLK PROTACS AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-05-23 | — | — | WO | disclosed |
| US-11969415-B1 | (methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-04-30 | — | — | US | disclosed |
| US-20240091206-A1 | COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREA | DECIPHERA PHARMACEUTICALS, LLC | 2024-03-21 | — | — | US | disclosed |
| CN-116675741-B | Application of intermediate in preparation of goserelin | 杭州湃肽生化科技有限公司 | 2023-10-31 | — | — | CN | disclosed |
| US-20220257574-A1 | COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHENYL)-3-PHENYLUREA | DECIPHERA PHARMACEUTICALS, LLC | 2022-08-18 | — | — | US | disclosed |
| US-20220160818-A1 | PHARMACEUTICAL COMPOSITIONS | RHYTHM PHARMACEUTICALS, INC. | 2022-05-26 | — | — | US | disclosed |
| EP-3966206-A1 | HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | Deciphera Pharmaceuticals, LLC (US) | 2022-03-16 | — | — | EP | disclosed |
| CN-114009789-A | Food for improving cardiovascular and cerebrovascular diseases and preparation process thereof | 刘严峰 | 2022-02-08 | — | — | CN | disclosed |
| US-H1056-H | Luteinizing hormone-releasing hormone | RHONE-POULENC CHIMIE, SERVICE BREVETS CHIMIE (FR) | 1992-05-05 | — | — | US | disclosed |
| JP-H035499-A | NEW PEPTIDE AND ITS PRODUCTION AND ITS USE | RHONE POULENC CHIM | 1991-01-11 | — | — | JP | disclosed |
| EP-0399885-A1 | Tripeptide, its process of preparation and its use | RHONE-POULENC CHIMIE (FR) | 1990-11-28 | — | — | EP | disclosed |
| US-4111923-A | LUTEINIZING HORMONE RELEASING FACTOR ANTAGONISTS | PARKE, DAVIS & COMPANY (US) | 1978-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12064422-B2 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea | PDGFRA, PDGFRB, KIT | OPRK1 648/4885OPRM1 2336/4885NPY4R 4111/4885 |
| US-20220160818-A1 | PHARMACEUTICAL COMPOSITIONS | PCTP, SLC27A1, CETP | OPRK1 1670/4885OPRM1 2320/4885NPY4R 839/4885 |
| US-20240091206-A1 | COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREA | PDGFRA, PDGFRB, KIT | OPRK1 648/4885OPRM1 2336/4885NPY4R 4111/4885 |
| US-20220257574-A1 | COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHENYL)-3-PHENYLUREA | PDGFRA, PDGFRB, KIT | OPRK1 720/4885OPRM1 2019/4885NPY4R 4039/4885 |
| US-12285460-B2 | Pharmaceutical compositions | PCTP, SLC27A1, CETP | OPRK1 1670/4885OPRM1 2320/4885NPY4R 839/4885 |
| US-20260053885-A1 | PHARMACEUTICAL COMPOSITIONS | ARGLU1, FFAR3, ASNS | OPRK1 1045/4885OPRM1 892/4885NPY4R 1183/4885 |
| US-11969415-B1 | (methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea | KIT, PDGFRA, PDGFRB | OPRK1 916/4885OPRM1 2466/4885NPY4R 4496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.